• ABOUT GlobeImmune
  • NEWSROOM
  • CAREERS
  • CONTACT US
  • INVESTORS
GlobeImmune
  • Platform
    • Product Pipeline
    • Tarmogen Platform
  • Cancer
    • Oncology Pipeline
    • GI-4000 / Mutated Ras
    • GI-6207 / CEA
    • GI-6301 / Brachyury
  • Infectious Disease
    • Infectious Disease Pipeline
    • GS-4774 / HBV
GlobeImmune  |  SEC Filings  |  D – 2014-03-12

D – 2014-03-12

Print
January 1, 1970

Notice of Exempt Offering of Securities

Archives

  • August 2014
  • February 2014
  • October 2013
  • September 2013
  • April 2013
  • January 2013
  • November 2012
  • July 2012
  • June 2012
  • May 2012
  • February 2012
  • October 2011
  • August 2011
  • June 2011
  • November 2010
  • October 2010
  • April 2010
  • March 2010
  • January 2010
  • November 2009
  • October 2009
  • May 2009
  • April 2009
  • November 2008
  • October 2008
  • September 2008
  • July 2008
  • June 2008
  • May 2008
  • March 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • January 2007
  • October 2006
  • August 2006
  • June 2006
  • May 2006
  • January 2006
  • December 2005
  • September 2005
  • August 2005
  • July 2005
  • January 2005
  • September 2004
  • August 2004
  • May 2004
  • December 2003
  • June 2003

Meta

  • Log in
  • SITE MAP »
  • CONTACT US »
  • CURRENT EMPLOYEES / INTRANET »

Copyright © GlobeImmune Inc. All Rights Reserved.

Corporate Headquarters
1450 Infinite Drive
Louisville, Colorado 80027
Phone: 720.667.2300